Roflumilast 500 Mcg Oral Tablet

DRUG4 trials

Sponsors

Johns Hopkins University, Jacob Pontoppidan Thyssen, University of Arizona, Tanta University

Conditions

AsthmaCAR T-Cell TherapyCell TherapyChronic Hand EczemaDonor Lymphocyte InfusionHematopoetic Stem Cell TransplantationLeukemiaLymphoma

Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

RecruitingNCT06643221

University of ArizonaCAR T-Cell Therapy, Cell Therapy, Donor Lymphocyte Infusion +3

Start: 2018-01-24End: 2028-12-30Target: 100Updated: 2024-10-16

Phase 2

Trial of Roflumilast in Asthma Management (TRIM)

CompletedNCT03532490

Johns Hopkins UniversityAsthma, Obesity

Start: 2018-08-03End: 2021-07-30Updated: 2022-10-06

Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH

CompletedNCT06677788

Tanta UniversityNon-Alcoholic Steatohepatitis (NASH)

Start: 2022-04-01End: 2024-10-15Updated: 2024-11-07

Phase 4

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

RecruitingNCT05682859

Jacob Pontoppidan ThyssenChronic Hand Eczema

Start: 2023-09-25End: 2026-04-01Target: 40Updated: 2023-11-18

Related Papers

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16+ NK cell–mediated cytotoxicity

Journal of Translational Medicine2026-03-03

Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia.

2026-01-15

Roflumilast May Increase Risk of Exacerbations When Used to Treat Poorly Controlled Asthma in People with Obesity.

2023-02-013 citations